FDA Inspection 1218067 — Samsung Biologics Co., Ltd.
The FDA completed an inspection of Samsung Biologics Co., Ltd. on Sep 1, 2023 in Yeonsu District. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Sep 1, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Yeonsu District (Korea (the Republic of))